| Literature DB >> 29940120 |
Nicole Blaquiere1, Georgette M Castanedo1, Jason D Burch1, Leonid M Berezhkovskiy1, Hans Brightbill1, Suzanne Brown1, Connie Chan1, Po-Chang Chiang1, James J Crawford1, Teresa Dong1, Peter Fan1, Jianwen Feng1, Nico Ghilardi1, Robert Godemann2, Emily Gogol1, Alice Grabbe2, Alison J Hole2, Baihua Hu3, Sarah G Hymowitz1, Moulay Hicham Alaoui Ismaili1, Hoa Le1, Patrick Lee1, Wyne Lee1, Xingyu Lin3, Ning Liu1, Paul A McEwan2, Brent McKenzie1, Hernani L Silvestre2, Eric Suto1, Swathi Sujatha-Bhaskar1, Guosheng Wu3, Lawren C Wu1, Yamin Zhang3, Zoe Zhong1, Steven T Staben1.
Abstract
NF-κB-inducing kinase (NIK) is a protein kinase central to the noncanonical NF-κB pathway downstream from multiple TNF receptor family members, including BAFF, which has been associated with B cell survival and maturation, dendritic cell activation, secondary lymphoid organ development, and bone metabolism. We report herein the discovery of lead chemical series of NIK inhibitors that were identified through a scaffold-hopping strategy using structure-based design. Electronic and steric properties of lead compounds were modified to address glutathione conjugation and amide hydrolysis. These highly potent compounds exhibited selective inhibition of LTβR-dependent p52 translocation and transcription of NF-κB2 related genes. Compound 4f is shown to have a favorable pharmacokinetic profile across species and to inhibit BAFF-induced B cell survival in vitro and reduce splenic marginal zone B cells in vivo.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29940120 DOI: 10.1021/acs.jmedchem.8b00678
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446